ALS Therapy DEvelopment Institute
Don’t see what you’re looking for? Use the search box on MDA’s Quest magazine.
Launched on World ALS Day, ALS TDI's ‘postcards’ share stories of people around the world who are working to stop ALS
Posted on Thursday, June 21, 2012 - 10:03, By: Other
On World ALS Day, June 21, 2012, the ALS Therapy Development Institute launched "ALS Postcards" as part of an international effort to raise awareness of amyotrophic lateral sclerosis (ALS) — known as motor neurone disease, or MND, in most parts of the world.
As progress continues in drug discovery and development at the ALS Therapy Development Institute, MDA's Augie's Quest provides $2 million more in support
Posted on Monday, March 5, 2012 - 06:00, By: Amy Madsen
MDA has extended its strategic research partnership with the ALS Therapy Development Institute (ALS TDI) through 2012 and awarded a $2 million grant to support the nonprofit biotech's continued efforts to develop treatments for ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease).
Through MDA's Augie's Quest program, the ALS Therapy Development Institute has been awarded an additional $2 million for drug development research
Posted on Wednesday, March 2, 2011 - 14:13, By: Amy Madsen
MDA has awarded $2 million to the ALS Therapy Development Institute (ALS TDI) in Cambridge, Mass., to help scientists complete the preclinical testing of four promising new compounds in ALS TDI's drug development pipeline.
The grant, made through MDA's Augie's Quest ALS fundraising initiative...
New mice, new projects and a newly added area of emphasis have been added to ALS TDI's preclinical drug development repertoire
Posted on Thursday, July 1, 2010 - 15:09, By: Amy Madsen
In continuing efforts to refine its preclinical drug development program, the ALS Therapy Development Institute (ALS TDI) of Cambridge, Mass., has added a new research mouse model to its operations, along with two new projects aimed at helping researchers test and develop therapies in the new mouse.
Posted on Saturday, May 1, 2010 - 11:43, By: ALSN Staff
IMMUNE SYSTEM MODULATOR HERALDS NEW STRATEGY IN ALS RESEARCH
Blocking a key molecular pathway that the body uses to amplify an immune response has been found to delay disease onset and extend survival in mice with a disease that mimics human ALS, say researchers at the MDA-supported ALS Therapy...
Motor neurons are lost in ALS, but new evidence shows they don't die without significant help from their neighboring cells. These neighbors may be easier to target with therapies than the motor neurons themselves.
Posted on Saturday, May 1, 2010 - 10:04, By: Margaret Wahl
Posted on Saturday, September 1, 2007 - 09:16, By: Margaret Wahl
Failure to recognize differences among mice with mutated SOD1 genes may be the key to understanding why so many medications that looked good in mouse studies later failed to benefit humans with ALS, say researchers at the MDA-supported ALS Therapy Development Institute (ALS TDI) in Cambridge,...